Maxim Group Downgrades Virpax Pharmaceuticals to Hold
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Naz Rahman has downgraded Virpax Pharmaceuticals (NASDAQ:VRPX) from Buy to Hold.
May 22, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Maxim Group analyst Naz Rahman has downgraded Virpax Pharmaceuticals from Buy to Hold, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less favorable view on the stock's potential, which could lead to a short-term decline in VRPX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100